was THB 453m which was 25% lower than Q1 2018 was THB 607m . Capital Expenditure Net Capital Expenditure was THB 180m in Q1 2019, and THB 266m in Q1 2018. Generally, capital expenditure for production
high at approximately 4 times current liabilities. Operating Cashflow (Recurring EBITDA) in Q2 2019 was THB 696m which was 9% lower than Q2 2018 was THB 765m. Capital Expenditure Net Capital Expenditure
Expenditure Capital Expenditure was THB 503m in Q2 2018, and THB 430m in Q2 2017. Generally, capital expenditure for production equipment will follow the increase in sales, particularly in the IC division
high at approximately 4 times current liabilities. Operating Cashflow (Recurring EBITDA) in Q3 2019 was THB 664m which was 40% lower than Q3 2018 was THB 1,098m. Capital Expenditure Net Capital
approximately 4 times current liabilities. Operating Cashflow (Recurring EBITDA) in Q1 2020 was THB 766m which was 68% higher than Q1 2019 was THB 455m. Capital Expenditure Net Capital Expenditure was THB 230m in
the employee benefits obligations approximately Baht 5.90 million. These were divided into two sections 1). cost of hospital operations in amounts of Baht 3.78 million. selling expense in amounts of
expenses, and other selling expenses such as marketing and promotional expenses, and depreciation of asset in each branch. In Quarter 1/ 2019 and Quarter 1/2018, the Company incurred selling expense totaling
% Administrative expenses (26.21) (39.92) (13.71) 52.31% Share of profit of investments in associate 0.09 0.13 0.04 46.78% Finance costs (0.26) (0.34) (0.07) 28.01% Profit before income tax expense 86.37 113.36
) 13.82% Administrative expenses (11.29) (7.77) 3.51 -31.13% Share of gain of investments in associate 0.03 0.03 0.00 0.25% Finance costs (0.08) (0.06) 0.02 -22.49% Profit before income tax expense 30.31
incurring higher expenditure concerning preparation for the pre-opening of Excellence Center in Early 2018. In addition, in 2017 the Company has benefited from its efficient excess liquidity management